Repositioning Candidate Details
| Candidate ID: | R1152 |
| Source ID: | DB08804 |
| Source Type: | approved; illicit |
| Compound Type: | small molecule |
| Compound Name: | Nandrolone decanoate |
| Synonyms: | 19-nortestosterone decanoate; Nandrolone 17β-decanoate; Nandrolone decanoate |
| Molecular Formula: | C28H44O3 |
| SMILES: | [H][C@@]12CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |
| Structure: |
|
| DrugBank Description: | Nandrolone decanoate, also known as nandrolone caprinate, is an alkylated anabolic steroid indicated in the management of anemia of renal insufficiency and as an adjunct therapy in the treatment of senile and postmenopausal osteoporosis. The process for creating esters of was patented in Spain in 1959 and in 1960, it was described as having a long duration of action and strong anabolic effect compared to nandrolone and other esters. Nandrolone decanoate was granted FDA approval on 5 October 1962. |
| CAS Number: | 360-70-3 |
| Molecular Weight: | 428.6472 |
| DrugBank Indication: | Nandrolone decanoate is indicated in the management of anemia of renal insufficiency. In Canada, it is also indicated as an adjunct therapy in the treatment of senile and postmenopausal osteoporosis. |
| DrugBank Pharmacology: | Nandrolone decanoate is an alkylated anabolic steroid indicated in the management of anemia of renal insufficiency and as an adjunct therapy in the treatment of senile and postmenopausal osteoporosis. It has a long duration of action as it is given every 3-4 weeks, and a wide therapeutic window as acute overdoses are rare. Patients should be counselled regarding the risks of giving this drug to patients with cardiac, renal, or hepatic diseases. |
| DrugBank MoA: | Nandrolone decanoate is hydrolyzed to , possibly by PDE7B. Nandrolone is brought into cells by receptor mediated endocytosis, where it interacts with the androgen receptor. After binding to the androgen receptor, a conformational change occurs, the androgen receptor enters the nucleus, dimerizes, and can then bind to segments of DNA to regulate transcription. Androgens can also regulate transcription through activation of ERK, Akt, and MAPK; or binding to and competitively inhibiting transcription factors. |
| Targets: | Androgen receptor agonist; Proto-oncogene c-Fos inducer; 5-hydroxytryptamine 2 receptor modulator; 5-hydroxytryptamine receptor 1B modulator; Insulin-like growth factor 1 receptor inducer; Dopamine receptor modulator |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |